New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

about

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

Item

http://www.wikidata.org/entity/Q47159366

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

@en

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

@nl

type

Item

label

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

@en

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

@nl

prefLabel

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

@en

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

@nl

P1476

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA

@en

P2093

Ana Blasco

http://www.w3.org/2001/XMLSchema#string

Carlos Camps

http://www.w3.org/2001/XMLSchema#string

Marina Meri

http://www.w3.org/2001/XMLSchema#string

Silvia Calabuig-Fariñas

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

P304

S1332-S1345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2017.06.112

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 13

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eloisa Jantus Lewintre

Cristóbal Aguilar

Elena Duréndez Sáez

A Azkarate

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29184672

http://www.w3.org/2001/XMLSchema#string

P932

5676108

http://www.w3.org/2001/XMLSchema#string